Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer
- PMID: 20865096
- PMCID: PMC2943186
Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer
Abstract
Recently, I put forth the hypothesis that the signaling molecule, norepinephrine (NE), is an etiological factor in a number of types of cancer. In this brief commentary, I summarize evidence that NE plays a role in cancer and describe details involved in testing the hypothesis in humans through epidemiological investigation of existing medical records of persons who have taken pharmaceutical drugs that affect NE. If NE plays an etiological role in cancers of a number of organs, then taking a single pharmaceutical drug (such as clonidine, prazosin, or propranolol) that weakens NE signaling systemically, may simultaneously prevent or treat many different types of cancer, and this may represent a breakthrough in pharmaceutical prevention and possibly treatment of cancer.
Keywords: acetylcholine; cancer; clonidine; norepinephrine; prazosin; propranolol.
References
-
- Fitzgerald PJ. Is norepinephrine an etiological factor in some types of cancer? Int J Cancer. 2009;124:257–263. - PubMed
-
- Gurkalo VK, Zabezhinskii MA, Pliss GB, Krylov SS. Adrenergic component in the hepatotropic, carcinogenic effect of diethylnitrosamine. Biull Eksp Biol Med. 1977;83:455–458. - PubMed
-
- Tatsuta M, Iishi H, Baba M, Nakaizumi A, Ichii M, Taniguchi H. Promotion by bombesin of gastric carcinogenesis induced by N-methyl-N’-nitro-N-nitrosoguanidine in Wistar rats. Cancer Res. 1989;49:5254–5257. - PubMed
-
- Sternbach H. Are antidepressants carcinogenic? A review of preclinical and clinical studies. J Clin Psychiatry. 2003;64:1153–1162. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
